Participation of older people in preauthorization trials of recently approved medicines

Journal of the American Geriatrics Society

Volumn 62, Issue 10, 2014, Pages 1883-1890

  Beers, Erna ^a   Moerkerken, Dineke C ^a   Leufkens, Hubert G M ^b,c   Egberts, Toine C G ^a,b   Jansen, Paul A F ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

clinical trial; exclusion; geriatric medicine; older participant; regulatory agency

Indexed keywords

AGOMELATINE; ASENAPINE; BAZEDOXIFENE; DABIGATRAN; DENOSUMAB; DRONEDARONE; ESLICARBAZEPINE; LASOFOXIFENE; LIRAGLUTIDE; RIVAROXABAN; SAXAGLIPTIN; VERNAKALANT;

AGED; AGING; ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL (TOPIC); DEPRESSION; EPILEPSY; FEMALE; GERIATRICS; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEDICINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OSTEOPOROSIS; PATIENT PARTICIPATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENESCENCE; VENOUS THROMBOEMBOLISM; ATRIAL FIBRILLATION; DIABETES MELLITUS, TYPE 2; EUROPE; RESEARCH SUBJECT; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BIPOLAR DISORDER; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEPRESSION; DIABETES MELLITUS, TYPE 2; EPILEPSY; EUROPE; GUIDELINES AS TOPIC; HUMANS; OSTEOPOROSIS; RESEARCH SUBJECTS; VENOUS THROMBOEMBOLISM;

EID: 84911972656     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.13067     Document Type: Article

References (45)

1. Fitzsimmons PR, Blayney S, Mina-Corkill S, et al. Older participants are frequently excluded from Parkinson's disease research. Parkinsonism Relat Disord 2012; 18: 585-589.
2. Mitchell SL, Sullivan EA, Lipsitz LA,. Exclusion of elderly subjects from clinical trials for Parkinson disease. Arch Neurol 1997; 54: 1393-1398.
3. Dodd KS, Saczynski JS, Zhao Y, et al. Exclusion of older adults and women from recent trials of acute coronary syndromes. J Am Geriatr Soc 2011; 59: 506-511.
4. Foerch C, Czapowski D, Misselwitz B, et al. Gender imbalances induced by age limits in stroke trials. Neuroepidemiology 2010; 35: 226-230.
5. Green P, Maurer MS, Foody JM, et al. Representation of older adults in the late-breaking clinical trials American Heart Association 2011 scientific sessions. J Am Coll Cardiol 2012; 60: 869-871.
6. Kitzman DW, Rich MW,. Age disparities in heart failure research. JAMA 2010; 304: 1950-1951.
7. Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 2011; 171: 550-556.
8. Yonemori K, Hirakawa A, Komiyama N, et al. Participation of elderly patients in registration trials for oncology drug applications in Japan. Ann Oncol 2010; 21: 2112-2118.
9. Talarico L, Chen G, Pazdur R,. Enrollment of elderly patients in clinical trials for cancer drug registration: A 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004; 22: 4626-4631.
10. Scher KS, Hurria A,. Under-representation of older adults in cancer registration trials: Known problem, little progress. J Clin Oncol 2012; 30: 2036-2038.
11. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
12. Clarfield AM, Friedman R,. Survey of the age structure of "age-relevant" articles in four general medical journals. J Am Geriatr Soc 1985; 33: 773-778.
13. Al-Refaie WB, Vickers SM, Zhong W, et al. Cancer trials versus the real world in the United States. Ann Surg 2011; 254: 438-442; discussion 442-443.
14. Dowd R, Recker RR, Heaney RP,. Study subjects and ordinary patients. Osteoporos Int 2000; 11: 533-536.
15. Hori A, Shibata T, Kami M, et al. Age disparity between a cancer population and participants in clinical trials submitted as a new drug application of anticancer drugs in Japan. Cancer 2007; 109: 2541-2546.
16. Sharpe N,. Clinical trials and the real world: Selection bias and generalisability of trial results. Cardiovasc Drugs Ther 2002; 16: 75-77.
17. Zimmerman M, Mattia JI, Posternak MA,. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002; 159: 469-473.
18. Uijen AA, Bakx JC, Mokkink HG, et al. Hypertension patients participating in trials differ in many aspects from patients treated in general practices. J Clin Epidemiol 2007; 60: 330-335.
19. McMurdo M,. Clinical research must include more older people. BMJ 2013; 346: f3899.
20. Cherubini A, Del Signore S, Ouslander J, et al. Fighting against age discrimination in clinical trials. J Am Geriatr Soc 2010; 58: 1791-1796.
21. Studies in Support of Special Populations: Geriatrics ICH E7 (CPMP/ICH/379/95). European Medicines Agency [on-line]. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002875.pdf Accessed April 22, 2014.
22. ICH topic E7 Studies in Support of Special Populations: Geriatrics; Questions and Answers. European Medicines Agency [on-line]. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/10/WC500005218.pdf Accessed April 22, 2014.
23. Adequacy of guidance on the Elderly Regarding Medicinal Products for Human Use. Committee for Medicinal Products for Human Use [on-line]. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/01/WC500049541.pdf Accessed April 22, 2014.
24. Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Errasquin B, et al. Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. J Am Geriatr Soc 2013; 61: 734-738.
25. Van Spall HG, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: A systematic sampling review. JAMA 2007; 297: 1233-1240.
26. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
27. European Medicines Agency [on-line]. Available at http://www.ema.europa.eu/ema/ Accessed April 22, 2014.
28. International Clinical Trials Registry Platform Search Portal. World Health Organization [on-line]. Available at http://apps.who.int/trialsearch/ Accessed April 22, 2014.
29. U.S. National Institute of Health Clinical Trials Registry. U.S. National Institutes of Health [on-line]. Available at http://www.clinicaltrials.gov/ Accessed April 22, 2014.
30. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821-831.
31. Population Pyramids of the World from 1950 to 2100.De WulfM [on-line]. Available at http://populationpyramid.net/ Accessed April 22, 2014.
32. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
33. Norberg J, Backstrom S, Jansson JH, et al. Estimating the prevalence of atrial fibrillation in a general population using validated electronic health data. Clin Epidemiol 2013; 5: 475-481.
34. Murphy NF, Simpson CR, Jhund PS, et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart 2007; 93: 606-612.
35. Kanis JA,. Assessment of Osteoporosis at the Primary Health Care Level. Sheffield, UK: World Health Organization Scientific Group, 2007.
36. Fablyn (lasofoxifene)-Cessation of Validity of the Marketing Authorisation in the European Union. European Medicines Agency [on-line]. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Public
37. Sander JW, Hart YM, Johnson AL, et al. National general practice study of epilepsy: Newly diagnosed epileptic seizures in a general population. Lancet 1990; 336: 1267-1271.
38. Zulman DM, Sussman JB, Chen X, et al. Examining the evidence: A systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 2011; 26: 783-790.
39. Konrat C, Boutron I, Trinquart L, et al. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One 2012; 7: e33559.
40. Leufkens HG, Urquhart J,. Variability in patterns of drug usage. J Pharm Pharmacol 1994; 46 (Suppl 1): 433-437.
41. Cerreta F, Eichler HG, Rasi G,. Drug policy for an aging population-the European Medicines Agency's geriatric medicines strategy. N Engl J Med 2012; 367: 1972-1974.
42. Diener L, Hugonot-Diener L, Alvino S, et al. Guidance synthesis. Medical research for and with older people in Europe: Proposed ethical guidance for good clinical practice: Ethical considerations. J Nutr Health Aging 2013; 17: 625-627.
43. PREDICT Charter for the Rights of Older People in Clinical Trials. PREDICT Consortium [on-line]. Available at http://www.predicteu.org/PREDICT-Charter/predict-charter.html Accessed April 22, 2014.
44. Briggs R, Robinson S, O'Neill D,. Ageism and clinical research. Ir Med J 2012; 105: 311-312.
45. National Institute For Health Research (NIHR) Clinical Research Network Website. National Institute for Health Research (NIHR) [on-line]. Available at http://www.crncc.nihr.ac.uk/ppi Accessed April 22, 2014.